CYTK | tickerfilter.com

Fundamental analysis

29%

Profitability 25%

Dept financing 25%

Liquidity 75%

Performance 21%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.42%

1 Month

-5.12%

3 Months

16.21%

6 Months

-21.90%

1 Year

62.07%

2 Year

11.86%

Key data

Stock price

$57.06

P/E Ratio

-12.32

DAY RANGE

$56.28 - N/A

EPS

-$5.37

52 WEEK RANGE

$25.98 - $110.25

52 WEEK CHANGE

$0.59

MARKET CAP

6.716 B

YIELD

N/A

SHARES OUTSTANDING

117.660 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

1.51

PUBLIC FLOAT

AVERAGE 10 VOLUME

$944,803

AVERAGE 30 VOLUME

$1,238,721

Company detail

CEO: Robert Blum
Region: US
Website: http://cytokinetics.com/
Employees: 447
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

CYTK - Cytokinetics Inc